Knowledge Library
Platform Supporting the Discovery of Agents against HSV
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) are globally prevalent human pathogens associated with a wide range of diseases, from mild conditions such as herpes labialis (cold sores) to serious infections such as encephalitis and meningitis. HSV can establish a lifelong latent infection in neurons of the peripheral nervous system and can reactivate …Read More >
Asthma Services Platform
Asthma is a chronic, lower airway disease characterized by persistent inflammation and hyperreactivity. Asthma involves a complex immune response, with T-helper 2 (Th2) cells playing a central role, leading to activation of eosinophils and increased levels of IgE antibodies. Clinically, airflow obstruction in asthma often is not fully reversible, and many asthmatic subjects experience an …Read More >
Production and Characterization of Protein Biologics
At the 2024 Protein & Antibody Engineering Summit (PEGS) Europe, Crelux presented a poster highlighting its drug discovery platform for the production and characterization of protein biologics and their antigens. This platform combines construct and expression scouting, customizable high-throughput protein purification, and affinity/kinetics determination using various biophysical techniques, as well as paratope and epitope mapping …Read More >
Targeted Protein Degradation Platform
Targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific disease-related proteins using cellular self-destruction mechanisms. This technology is enabling researchers to pursue targets that were previously considered undruggable and to address the resistance issue of small molecule inhibitors. Since 2016, WuXi AppTec has built a comprehensive TPD discovery …Read More >
Toxicology Profile of a Novel GLP-1 Receptor Agonist
Glucagon‐like peptide‐1 (GLP-1) receptor agonists have emerged as promising therapeutic options for addressing type‐2 diabetes, obesity, and related conditions. However, because of the continued need for injectable administration, many GLP-1 agonists face compliance challenges. To improve the design and production of GLP-1 receptor biased agonists with enhanced druggability, a novel small molecule, designated SAL0112, was …Read More >
Evaluation of Bispecific Antibodies in NHPs
In recent years, bispecific antibodies (BsAbs) have emerged as a novel strategy in tumor immunotherapy. BsAbs combine two distinct antigen targets within a single antibody molecule, potentially enhancing clinical efficacy and safety. As a result of this dual targeting approach, the clinical therapeutic effects of BsAbs are considered superior to those of monoclonal antibodies. WuXi …Read More >
USP7 Inhibitors Reveal a Differentiated Mechanism of p53-Driven Anti-Cancer Activity
Ubiquitin-specific protease 7 (USP7) is a deubiquitinating enzyme that cleaves ubiquitin from a range of substrates, shielding them from degradation by the proteasome. USP7 activity has been implicated in cancer progression and its overexpression is associated with tumor aggressiveness and poor prognosis in a variety of cancer types, making USP7 inhibition an attractive strategy for …Read More >
ErbB Receptor Tyrosine Kinase Platform
The ErbB family of receptor tyrosine kinases are involved in key cellular functions, including cell growth and survival. ErbB family members are often overexpressed, amplified, or mutated in many forms of cancer, making them important therapeutic targets. To support research focused on ErbB receptors, WuXi AppTec offers a comprehensive platform of ready-to-go biophysical assays, high-quality …Read More >
Phosphatidylinositol Kinases: Structural Biology Services
Within the phosphatidylinositol 3-kinase (PI3K) family, the heterodimer comprising the p110-α catalytic and p85-α regulatory subunits (encoded by PIK3CA and PIK3R1) is essential in the regulation of cellular proliferation and carcinogenesis. Kinases such as PIK3CA are mutated in many cancers and represent promising targets for therapeutics. To support drug discovery programs, we have established off-the-shelf …Read More >